Equillium announces abstract accepted for oral presentation at the transplantation & cellular therapy meetings of astct and cibmtr

La jolla, calif.--( business wire )--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for oral presentation at the transplantation & cellular therapy meetings of the american society of transplantation and cellular therapy, and the center for international blood & marrow transplant research. the hybrid meetings will take place virtually and in person at the orlando world center marriott, orlando, florida, february 15 – 19, 2023.
EQ Ratings Summary
EQ Quant Ranking